Immunogen (FRA:IMU) Deferred Tax : €0.0 Mil (TTM As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Immunogen Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Immunogen's change in deferred tax for the three months ended in Sep. 2023 was €0.0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2023 was €0.0 Mil.

Immunogen Deferred Tax Historical Data

The historical data trend for Immunogen's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Deferred Tax Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Deferred Tax

Get a 7-Day Free Trial

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Immunogen Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Immunogen Deferred Tax Related Terms

Thank you for viewing the detailed overview of Immunogen's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (FRA:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

IMGN:USA IMGN:Mexico

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Immunogen (FRA:IMU) Headlines

No Headlines